Regulated Product Submissions R1 Overview January 12 th HL7 WGM Jason Rock 215-253-7474.

Slides:



Advertisements
Similar presentations
Vilnius, 29 June 2007 CIOMS Recommendations on Ethics in Medical Research The Eighth Global Forum on Bioethics in Research Gottfried Kreutz Dr. med., Dipl.-Chem.;
Advertisements

Helmut König, Siemens Medical Solutions
EDOS Workgroup Update July 16, 2013 Laboratory Orders Interface Initiative.
Longitudinal Coordination of Care LTPAC SWG Monday, April 29, 2013.
EDOS Workgroup Update HL7 Orders & Observation WG May 7, 2013 Laboratory Orders Interface Initiative.
EDOS Workgroup Update June 18, 2013 Laboratory Orders Interface Initiative.
Depicting EHRs Immunization capability HL7 WGM – September 11, 2006 Immunization Storyboard project update.
© 2011 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International.
RCRIM September 2007 Working Group Meeting Clinical Research Filtered Query Service Tuesday, September 18, 2007 (Q4) Sheraton Hotel Atlanta, GA.
HL7 Version 3 Laboratory Result-based Adverse Event Assessment Message Specifications RCRIM Technical Meeting September 18, 2007 Jennifer Neat Project.
HL7 January Working Group Meeting
1 HL7 Jan 2007 Working Group MeetingsPharmacogenomics Update RCRIM TC Philip M. Pochon Covance Enterprise Architecture.
RPS 2 Project Update Mary Ann Slack, FDA Presentation to HL7 RCRIM January 12, 2009.
Joint TC Meeting: EHR – RCRIM RCRIM Overview HL7 Working Group Meeting January, 2007 Presented by: Ed Tripp Program Director, eSubmissions Abbott (RCRIM.
CDISC Content to Message HL7 Development Overview Jason Rock
1 HL7 Jan 2010 Working Group MeetingsCTLAB Pharmacogenomics Update JOINT RCRIM and CG Session CTLAB Message Pharmacogenomics Results Overview.
CDISC-HL7 Project Update Armando Oliva, M.D. FDA Sponsor HL7 Workgroup Meeting January 14, 2008 San Antonio TX.
Regulated Product Submissions Release 2 Iteration 1 Design January 12th HL7 WGM Jason Rock
Clinical Genomics Sub-team Sub-team is one of three that evolved out of the DIA Pharmacogenomics Standards Workshop. Workshop was product of collaborative.
BRIDG Overview Clinical Observation Interoperability March 18, 2008.
ISO/TS WHO Informal Consultation on Nomenclatures for Medical Devices March 23-24, 2011 Leighton Hansel Convener ISO/TC210 WG3 Symbols and Nomenclature.
The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.
Strengthening the Medical Device Clinical Trial Enterprise
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
Regulatory Overview.
Good Clinical Practice GCP overview
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
HL7 Study Data Standards Project Crystal Allard CDER Office of Computational Science Food and Drug Administration February 13,
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.
PhUSE Computational Science Working Groups Solutions Through Collaboration.
UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.
RCRIM Off-cycle Meeting Barbara Tardiff, Randy Levin and Ed Tripp, co-chairs.
510(k) Submissions Recent Experience and Perspectives Terry Sullivan Vice President, Regulatory Affairs.
Regulated Product Submission HL7 Update Wednesday January 10 th, 2007 Jason Rock
EDOS Workgroup Update May 21, 2013 Laboratory Orders Interface Initiative.
Overview of FDA's Regulatory Framework for PET Drugs
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.
1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.
Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
Regulation of Generic Animal Drugs in the United States
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.
DIA Trial Master File Reference Model
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.
Regulated Product Submission Standard Overview Peggy Leizear FDA.
Regulated Product Submissions Goals and Scope Jason Rock x105.
ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.
RAC Regulatory Affairs Certification
CTD Content Management
Data Managers’ Forum What’s in it for us?
Kimby N. Barton Interim Director Medical Devices Bureau
Women’s Health Technologies CRN
Percentage Key Message
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Fundamentals of Electronic Submissions and eCTD
Business View on eCTD v4.0 Advantages and challenges when considering implementation to overcome constrains of the current eCTD specification.
January, 2004 Project: IEEE P Working Group for Wireless Personal Area Networks (WPANs) Submission Title: [January 1394-Wireless Working Group Liaison.
Opening an IND: Investigator Perspective
January, 2004 Project: IEEE P Working Group for Wireless Personal Area Networks (WPANs) Submission Title: [January 1394-Wireless Working Group Liaison.
Presentation transcript:

Regulated Product Submissions R1 Overview January 12 th HL7 WGM Jason Rock

Table of Contents Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

Goal Create one model that can be used for the submission of any regulated product –Create a framework that will allow sponsors to send regulatory information using predefined parameters to identify and catalog their content –Reviewers will be able to consistently locate discipline specific information

Scope Animal and Human products –Including but not limited to food additives, human therapeutics, veterinary products, and medical devices Worldwide use –Same model for all product types to all regulatory authorities

Out of Scope Document content will not change –Documentation submitted today will be the same documentation submitted tomorrow Must work within existing business processes –We hope since Applicants and Regulatory Authorities from varied product types are talking we can learn from each other and enhance our process as it suits our needs

Design Decisions Clear communication –The meaning of the content that is sent is the same meaning of the content that is received –Submitted documentation will be clearly identified using predefined parameters Different predefined parameters for different submission types and regulatory authority (controlled vocabulary) XML catalogs the content (not intended to be read directly)

Work to date RPS Project initiated June 22 nd 2005 –Leveraged existing Human Pharmaceuticals experience (ICH/eCTD) Draft Standard for Trial Use (DSTU) – Passed May 2006 Distributed sample message Testing kick-off June 18 th 2006 First test submission submitted to FDA Sept Harmonized with BRIDG March 2007 Normative Ballot – Passed April 2007 ANSI approved – March 2008

Submission Hierarchy Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

Application Submission - Supplement Submission - Original Submission Unit Submission Hierarchy OriginalAmendment SupplementAmendment

Submission - Original Reviewable Unit Tox Amendment CMC Reviewable Unit Amendment Efficacy Amendment Submission Unit

Documentation in submission Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

Context of Use Submission Unit Original Context of Use Protocol Intro Report The collection of files provided to the Regulatory Authority at one time

Keywords Context of Use Protocol Report Keywords are used to further define the context of documentation. Types defined by regulatory authority (e.g. manufacturer, study), value define by business (e.g. Acme, Study 12345) Documentation submitted to support a regulatory review Manufacturer Study Acme Keywords documentation for Double Blind

Submission Reviewing Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

View Application Submission - Original Submission Unit Original Supplement Submission - Supplement Keywords are used to further refine the table of contents.

View (2) Application Submission Keyword Context of Use Submission Unit Reviewable Units are not shown

RMIM and XML Instance Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance

RPS Release 1

Controlled vocabulary For differing submission types and regulatory authorities –Application (MAA, PMA, 510K, etc.) –Submission (original, supplement, etc.) –Submission units (original, amendment, etc.) –Documentation (synopsis, protocol, summary of clinical, etc.) Created by Regulatory Authorities (GHTF, ICH, working with industry)

Sample Instance

Recap Overview and background Submission Hierarchy Documentation in submission Submission Reviewing RMIM and XML Instance